Oral Presentation

Monday, September 26th 2011

323. COPD: burden of disease, imaging and management

2953 Late-breaking abstract: Nasal symptoms are common in subjects with COPD and concomitant heart disease

Anne Lindberg1, Lars Gunnar Larsson2, Eva Ronmark3, Bo Lundback4

1 Department of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Umeå, Sweden; 2 The OLIN studies, Department of Respiratory Medicine, Sunderby Hospital, Umeå, Sweden; 3 Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, Umeå University, Umeå, Sweden; 4 Department of Internal Medicine/Krefting Research Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

Background: Systemic inflammation has been suggested as a possible link between cardiovascular and airway disease in COPD. Symptoms related to nasal inflammation and CV disease have been discussed in relation to COPD and systemic inflammation. Coincident data on these conditions are scarce.

Aim: To give descriptive population based data on CV disease and nasal symptoms in COPD and non-COPD.

Methods: All subjects with COPD according to GOLD, FEV1/FVC <0.70, were identified (n=993) from clinical follow-ups in 2002-04 of the OLIN (Obstructive Lung Disease in Northern Sweden) study2 cohorts together with 993 gender and age-matched reference subjects without COPD (non-COPD, further divided into normal and restrictive lung function, Nlf and Rlf). Interview-data on nasal symptoms and CV disease were used.

Results: CV disease (heart disease (HD), hypertension, stroke, claudication) was more prevalent in COPD compared to in Nlf; 50.1% vs 41.0% (p<0.001) and also the prevalence of HD (angina pectoris, heart failure, myocardial infarction), 18.5% and 13.7%, respectively (p=0.006). Nasal symptoms were more common in COPD compared to in Nlf, 43.1% vs 32.3%, p<0.001. In Rlf the prevalence of nasal symptoms, CV disease and HD were 41.0%, 59.0% and 24.4%, significantly higher compared to in Nlf (p<0.017, p<0.001 and p<0.001) and all but nasal symptoms also compared to in COPD (p=0.573, p=0.047 and p=0.017). In subjects with COPD and HD, 53.0% had nasal symptoms, while 35.8% in Nlf and 62.2% in Rlf.

Conclusion: Cardiovascular disease and nasal symptoms were common in COPD, and Rlf did also identify a population with increased CV disease burden. The overlap between heart disease and nasal symptoms was large in subjects with COPD but also in Rlf.

2954 Prevalence of COPD in a rural population in India

Sundeep Salvi1, Sanjay Juvekar2, Jiotti Londhe2, Bill Brashier3, Sapna Madu4, Peter Barnes3

1 Clinical Research, Chest Research Foundation, Pune, Maharashtra, India; 2 Vuda Rural Health Centre, King Edward Memorial Hospital Research Centre, Pune, Maharashtra, India; 3 Respiratory Medicine, Imperial College, London, United Kingdom

COPD is a growing cause of morbidity and mortality across the world. However, there is little data on the burden of COPD in India, especially in the rural population.

Aim: We aimed to study the prevalence and risk factors for COPD in a rural population in India using the Burden of Obstructive Lung Disease (BOLD) study protocol.

Methods: 3600 male and female subjects above the age of 25 years residing in 22 rural villages near Pune were randomly selected to participate in the study. 10 trained field workers visited their homes, and after obtaining written informed consent, administered the BOLD questionnaire and performed pre and post-bronchodilator spirometry using ndd sprirometer. COPD was defined as post-bronchodilator FEV1/FVC <0.70.

Results: 2699 subjects (M: 49.9%; F: 50.1%) with a mean age 43.8±14.5 yrs consented. Acceptable spirometry was obtained from 1745 subjects. The overall prevalence of COPD was found to be 5.1% (M:6.5%; F:3.4%) and 85% of these never smoked. Male gender [Adj OR: 1.93 (CI 1.2-3.3); p=0.01] and increasing age [OR: 2.01 (CI 1.7-2.4); p<0.001] were strongly associated with COPD. 70% of the COPDs lived in homes that used biomass fuel for cooking compared to 30% who used liquefied petroleum gas (LPG). Tobacco smoking on its own was significantly associated with COPD [OR: 2.34 (CI 1.2-4.3); p=0.006], however, after adjustment, the risk reduced [Adj OR: 1.88 (CI: 0.96-3.7); p=0.06]. Smokers who used biomass fuel had a 3.2-fold higher prevalence of COPD than non-smokers using LPG (p=0.01).

Conclusion: COPD is more common amongst non-smokers in the rural population in India although smoking is a risk factor for COPD. Smokers who use biomass fuel for cooking have a significant additive risk of COPD.

2955 Using the lower limit of normal to classify lung disease misses at risk people

David Mannino, Enrique Diaz 

Pulmonary and Critical Care Medicine, University of Kentucky, Lexington, United States

Objective: To determine mortality in a representative sample of the U.S. adult population comparing abnormality determined using GOLD criteria to that determined using LLN criteria.

Methods: We used baseline data from the Third National Health and Nutrition Examination Survey (NHANES III) and follow-up mortality data. We classified subjects as obstructed, restricted, or normal based on the GOLD vs. the LLN criteria. We used Cox proportional hazards models to determine the relation between diagnosed lung disease and mortality, adjusting for covariates.

Results: Our study sample included 13,847 subjects, of whom 3,774 died during the follow-up period. Of subjects classified as obstructed and restricted using GOLD criteria, 20.9% and 18.0% were classified as normal using the LLN. Mortality was increased in the obstructed hazard ratio (HR) 1.48, 95% confidence interval (CI) 1.21, 1.80 and restricted HR 2.03, 95% CI 1.67, 2.45 subjects classified as normal using the LLN, but abnormal using the GOLD criteria.

Conclusion: In the nationally representative NHANES III data, subjects classified as normal using the LLN criteria but obstructed or restricted using the GOLD criteria have a higher risk of mortality.

2956 Ten-year trend in the prevalence of chronic cough and phlegm among young adults in Italy

Simone Accordini1, Veronica Cappa1, Isa Cervetti2, Cristina Bombieri2, Massimiliano Bugiani3, Lucio Casali3, Lucia Cazzolleti3, Angelo Corsi3, Marcello Ferrari3, Virginia Ferretti3, Alessandro Foss4, Francesca Locatelli5, Alessandro Marconi5, Mario Olivieri5, Pietro Pima5, Roberto de Marco5

1 Unit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy; 2 Division of Respiratory Diseases, IRCCS Sant Matteo Hospital Foundation, University of Pavia, Pavia, Italy; 3 Unit of Biology and Genetics, University of Verona, Verona, Italy; 4 Unit of Pneumology, Local Health Agency ASL TO2, Turin, Italy; 5 Department of Internal Medicine, Section of Respiratory Diseases, University of Perugia, Perugia, Italy; 6 Section of Internal Medicine, University of Verona, Verona, Italy; 7 Department of Applied Health Sciences, University of Pavia, Pavia, Italy; 8 Institute of Respiratory Diseases, University of Sassari, Sassari, Italy; 9 Unit of Occupational Medicine, Azienda Ospedaliera Istituti Ospitalieri di Verona, Verona, Italy

The presence of chronic cough and phlegm (on most days for a minimum of 3 months a year and for at least 2 successive years) identifies a subgroup of subjects with a high risk of developing COPD, independently of smoking habits. We sought to evaluate the ten-year trend in the prevalence of these symptoms among young adults in Italy.

In 1998/2000, a screening questionnaire was mailed up to 3 times to general population samples of 20-44 year-old subjects, and eventually given over the phone to the remaining non-responders, in the Italian Study on Asthma in Young Adults (ISAYA) (9 centres; response rate = 72.5%). The same procedure was repeated in the Gene Environment Interactions in Respiratory Diseases (GEIRD) study in 2007/2010 (7 centres; response rate = 57.2%).

In the 4 centres (Pavia, Sassari, Turin, Verona) involved in both the studies, the adjusted prevalence* of current smokers has decreased (from 34.3% to 27.4%; p<0.001) during the past decade. The adjusted prevalence of chronic cough and phlegm (with the 95%CI) is reported in this table:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smokers</td>
<td>Past smokers</td>
<td>Current smokers</td>
</tr>
<tr>
<td>(n=9531)</td>
<td>(n=5162)</td>
<td></td>
</tr>
<tr>
<td>7.5% (7.1-7.9)</td>
<td>11.2% (10.6-11.9)</td>
<td>19.3% (18.4-20.2)</td>
</tr>
<tr>
<td>9.1% (8.2-10.1)</td>
<td>10.4% (9.8-10.9)</td>
<td>21.5% (18.4-24.3)</td>
</tr>
</tbody>
</table>

*Adjusted for centre, type of contact (telephone vs mail), cumulative response rate, season of response, sex, age.

The overall prevalence of chronic cough and phlegm has not changed during the past decade among young adults in Italy, but a decrease is expected due to the observed reduction in the percentage of current smokers. The increase in the prevalence among non-smokers deserves further investigation.
Costs of COPD by disease severity
Sven-Arne Jansson1, Helena Backman1, Anna Steingård1, Anne Lindberg1,2, Eva Rommak1,2, Bo Lundback1,2.1. The OLIN Studies, Norrbotten County Council, Luåda, Sweden; 2.Astrazeneca Nordic, Astrazeneca Nordic, Södertälje, Sweden; 3.Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 4.Department of Internal Medicine/Respiratory Medicine and Allergology, University of Gothenburg, Gothenburg, Sweden

Background: Chronic obstructive pulmonary disease (COPD) is one of the most common chronic and disabling diseases worldwide, and the societal costs are high. Aim: To estimate the societal costs of COPD in Sweden and to examine the relationship between disease severity and costs.

Methods: The study sample was identified in earlier clinical examinations of general population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden) studies. The cohort consisted initially of 993 subjects fulfilling COPD spirometric criteria (GOLD). In 2009-2010, telephone interviews on resource utilization were made to a sample of 244 subjects, stratified by disease severity. Interviews were performed quarterly to minimize the risk of recall bias. A non-parametric Mann-Whitney U-test was used to test cost differences between groups; p-values adjusted by Bonferroni correction. Unit costs from 2010 were applied.

Results: A highly significant relationship was found between disease severity and costs. The mean annual total cost per patient in relation to disease severity (GOLD) was: stage I €4,811, II €5,266, III €7,068, and IV €20,665. Indirect costs were higher than direct costs in all severity stages. For direct costs, main cost drivers were hospitalizations in stage III and IV, and drugs in stage I and II, respectively. The main cost driver in indirect costs was productivity loss due to early retirement, except in stage I where the driver was sick-leave. In comparison with a similar study performed in 1999 a numerical increase in mean annual total costs per patient was observed (ns).

Conclusions: The results indicate that the societal costs of COPD in Sweden are substantial, and the costs increase considerably by disease severity.

2958 Associations between quantitative computed tomography (qCT) measures of emphysema and mortality
Anne Johannessen1, Trude Duelien Skorge2, Thomas Blix Gyldeyland3, Harvey Coxson4,5,6, Ernst Omenaas1,6, Amund Gulsvik4,5,6, Per Bakke4,6,7, Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway; 2Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway; 3Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway; 4Institute of Medicine, University of Bergen, Bergen, Norway; 5Pulmonary Medicine, Hospital Miguel Servet, Pamplona, Navarra, Spain; 6Pulmonary and Critical Care, St. Elizabeth’s Medical Center, Boston, MA, United States; 5Pulmonary Medicine, Hospital Universitario de Canarias, Tenerife, Spain; 7Pulmonary and Critical Care, Gilead Sciences, Seattle, WA, United States; 3Department of Medicine, University of Washington, Seattle, WA, United States; 4Health Services Research and Development, VA Puget Sound Health Care System, Seattle, WA, United States; 2Department of Respiratory Clinical Research, Gilead Sciences, Seattle, WA, United States;

Background: Knowledge is limited regarding associations between qCT measures of emphysema and mortality. Aims: To examine 6-year mortality (all-cause and chronic lower airway diseases mortality) of COPD patients. Methods: In the Norwegian GenKOLS study 2003-05, 947 ever-smokers (49% with COPD) aged 40-85 years performed spirometry and qCT examination. Lung inflation level was obtained by dividing CT measured lung volume by predicted TLC. CT emphysema was estimated using% of lung voxels with X-ray attenuation values less than -950 Hounsfield units (% low-attenuation areas (%LAA)), expressed as quintiles. Mortality data from 2003-09 were gathered from the Norwegian Cause of Death Registry. Gender-stratified Cox proportional hazards were modelled, adjusting for FEV1, COPD status, age, BMI, smoking, inflation level. Results: Both all-cause (n=106) and chronic lower airway diseases mortality (n=31) increased with%LAA from 3% and 0.5% in the lowest quintile to 32% and 12% in the highest quintile. Unadjusted hazard ratios (HR) (95% CI) for all-cause mortality were 14.1 (6.2, 32.0) for the highest quintile for women, and 8.4 (4.4, 16.1) for men. After adjustment, the trends remained the same, but were (borderline) significant only for women (HR 3.7 (95% CI 0.9, 14.3). For chronic lower airway mortality, the highest quintile%LAA had HR (95% CI) 47.2 (6.3, 377) for women, and 8.4 (4.4, 16.1) for men. After adjustment, upper%LAA quintile had HR 17.6 (95% CI 3.08, for women and 2.5 (0.47, for men.

Conclusions: The results indicate that the qCT measures of emphysema are related to mortality, especially in women. Subjects with high%LAA have a substantially elevated mortality risk.

2959 Impact of comorbidities on survival of patients with COPD according to GOLD stages
Zagacta Jorge1, Cabrera Carlos2, Divo Miguel3, Cote Claudia1, Juan De Torres1, Joselina Maria2, Ciro Casanova2, Victor Pinto-Plata3, Santiago Carriazo1, Maria Sanchez-Carpintero1, Javier Zuhaitz1, Bartolome Celli1,1. Pulmonary Medicine, Clínica Universidad de Navarra, Pamplona, Navarra, Spain; 2Pulmonary Medicine, Hospital Universitario Dr. Negrín, Las Palmas de G.C., Canarias, Spain; 3Pulmonary and Critical Care, Brigham and Women’s Hospital, Boston, MA, United States; 4Pulmonary and Critical Care, Bay Pines Veterans Affairs Medical Center, Bay Pines, FL, United States; 5Pulmonary Medicine, Hospital Miguel Servet, Zaragoza, Spain; 6Pulmonary Medicine, Hospital Nuestra Senora de la Candelaria, Tenerife, Spain; 7Pulmonary and Critical Care, St. Elizabeth’s Medical Center, Boston, MA, United States

Introduction: In COPD patients the impact of comorbidities on patient’s outcomes is gaining interest. The aim of our study is to describe the role of comorbidities on mortality according to COPD GOLD stages.

Methods: We enrolled and followed 1664 patients from the BODE cohort over 10 years in five tertiary centers in the USA and Spain. Demographics, anthropometrics, physiological, comorbidities and survival with cause of death were recorded systematically. Patients were grouped according to GOLD stages I-II, III and IV. Tukey’s test was used to compare means among groups. A multivariate analysis was used to select those comorbidities associated with mortality. The effect of comorbidities over survival time was explored using Cox proportional hazard.

Results: Groups characteristics and differences are shown in table 1. GOLD IV subjects were significantly younger, had fewer comorbidities and higher mortality. Furthermore comorbidities did not influence mortality in these subject and they died mainly from COPD (Table 2 and 3).

2960 Glitazones are associated with reduced risk of COPD exacerbations and mortality among patients with diabetes
David Au1,2, Thomas O’Riordan1, Chun-Fen Liu1,4, Mark Perkins1, John Toole2, Christopher Bryson1,3,1. Health Services Research and Development, VA Puget Sound Health Care System, Seattle, WA, United States; 2Department of Respiratory Clinical Research, Gilead Sciences, Seattle, WA, United States; 3Department of Medicine, University of Washington, Seattle, WA, United States; 4Health Services Research, University of Washington, Seattle, WA, United States

Introduction: Moderators of systemic inflammation may reduce risk of exacerbations among patients with COPD. Glitazones, used in the treatment of diabetes, also have anti-inflammatory properties. We sought to assess whether glitazones were associated with a decreased risk of COPD exacerbations and mortality.

Study design: We performed a cohort study between 10/2005-09/2006 of all US veterans who received an oral antihyperglycemic medication (sulfonylurases, biguanides, or glitazones) on more than one occasion. Our outcome measures included outpatient COPD exacerbations, hospitalization for COPD, and all cause mortality. Our primary exposure was glitazone use compared to sulfonylurase and/or biguanides. We used GEE to estimate the effect of glitazones and to adjust for potential confounding factors.

Results: We identified 600,366 patients. Adjustment for age, sociodemographic characteristics, comorbidity, and markers of COPD severity had minimal effects on the point estimates. In comparison to either a sulfonylurea or biguanide, glitazone were associated with a significantly reduced risk of outpatient exacerbation (Adjusted relative likelihood (Adj-RL, 0.79 (0.72-0.86), hospitalization for COPD exacerbation (Adj-RL, 0.95 (0.82 (0.69-0.97)) and all cause mortality (Adj-RL, 0.95 (0.89 (0.85-0.93)). These estimates were robust to sensitivity analyses that imposed increasingly strict definitions of COPD.

Discussion: Glitazones were associated with a significant reduction in COPD exacerbations and all cause mortality. We hypothesize that this association may be mediated through the anti-inflammatory properties of glitazones. Funding: Gilead Sciences, Inc., & VA HSRD